Nancy J. Curtin
Affiliations: | History | Fordham University, Bronx, NY, United States |
Area:
European History, International Relations, General HistoryGoogle:
"Nancy Curtin"Children
Sign in to add trainee| Michael Conforti | grad student | 2012 | Fordham University |
| Johnathan M. Pettinato | grad student | 2014 | Fordham University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Batey MA, Zhao Y, Kyle S, et al. (2013) Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Molecular Cancer Therapeutics. 12: 959-67 |
| Chen T, Stephens PA, Middleton FK, et al. (2012) Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today. 17: 194-202 |
| Peasland A, Wang LZ, Rowling E, et al. (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer. 105: 372-81 |
| Shaheen FS, Znojek P, Fisher A, et al. (2011) Targeting the DNA double strand break repair machinery in prostate cancer. Plos One. 6: e20311 |
| Kyle S, Thomas HD, Mitchell J, et al. (2008) Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. The British Journal of Radiology. 81: S6-11 |
| Zaremba T, Curtin NJ. (2007) PARP inhibitor development for systemic cancer targeting. Anti-Cancer Agents in Medicinal Chemistry. 7: 515-23 |
| Zhao Y, Thomas HD, Batey MA, et al. (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Research. 66: 5354-62 |
| Curtin NJ. (2005) PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine. 7: 1-20 |